Loading...
Pharmacokinetics, immunogenicity, safety, and preliminary efficacy of subcutaneous turoctocog alfa pegol in previously treated patients with severe hemophilia A (alleviate 1)
BACKGROUND: The current standard of care for patients with hemophilia A is regular prophylaxis with factor VIII (FVIII) administered intravenously. Interest in subcutaneous (s.c.) administration, to potentially increase convenience, reduce the treatment burden and improve compliance, is increasing....
Na minha lista:
| Udgivet i: | J Thromb Haemost |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
John Wiley and Sons Inc.
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7027501/ https://ncbi.nlm.nih.gov/pubmed/31618804 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jth.14660 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|